Copertina

GLP ‐1 receptor agonists versus testosterone in male reproductive health: A critical perspective

Fuente: Wiley Open Access

Salvato in:

Dettagli Bibliografici
Autori principali:	João Oliveira Torres, Mariana Guilherme Lima, Bruno Bouça, José Silva‐Nunes
Natura:	Artículo Open Access
Pubblicazione:	Wiley 2025
Soggetti:	Diabetes, Obesity and Metabolism
Accesso online:	Acceder al recurso
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!

Documenti analoghi

GLP ‐1 receptor agonists and cardiovascular events in metabolically healthy or unhealthy obesity
di: Tommaso Bucci, et al.
Pubblicazione: (2025)

Digital engagement enhances dual GIP / GLP ‐1 receptor agonist and GLP ‐1 receptor agonist efficacy: A retrospective cohort analysis of a digital weight loss service on outcomes and safety
di: Hans Johnson, et al.
Pubblicazione: (2025)

Psychiatric effects of GLP ‐1 receptor agonists: A systematic review of emerging evidence
di: Brianna Sa, et al.
Pubblicazione: (2025)

The extent and predictors of off‐label use of GLP ‐1 receptor agonists for weight loss management
di: Zbigniew Siudak, et al.
Pubblicazione: (2025)

Cardiorenal outcomes and mortality with GLP ‐1 receptor agonists combined with SGLT2 inhibitors in type 2 diabetes: An updated systematic review and meta‐analysis
di: João Sérgio Neves, et al.
Pubblicazione: (2025)

Comparative healthcare resource utilization and costs of empagliflozin and GLP ‐1 receptor agonists in type 2 diabetes
di: Phyo Than Htoo, et al.
Pubblicazione: (2025)

Beyond diabetes and obesity: GLP ‐1 receptor agonists in disrupting the vicious cycle of metabolic dysfunction and neuroinflammation
di: Renata Spezani, et al.
Pubblicazione: (2025)

Cardiovascular and kidney outcomes of GLP ‐1 receptor agonists in adults with obesity: A target trial emulation study
di: Huilin Tang, et al.
Pubblicazione: (2025)

Effectiveness and safety of GLP ‐1 receptor agonists in craniopharyngioma patients with obesity: A multicentre real‐world study
di: Flora Lambert, et al.
Pubblicazione: (2025)

Adherence to GLP ‐1 receptor agonists and SGLT2 inhibitors by out‐of‐pocket spending among Medicare beneficiaries with diabetes
di: Nicklas S. Klepser, et al.
Pubblicazione: (2025)

GLP ‐1 receptor agonists for treating obesity without diabetes: A systematic review and meta‐analysis of economic evaluations
di: Teerapon Dhippayom, et al.
Pubblicazione: (2025)

Long‐term delirium and survival outcomes in patients treated with GLP ‐1 receptor agonists versus metformin in type 2 diabetes: A population‐based cohort study
di: Mingyang Sun, et al.
Pubblicazione: (2025)

Sex differences in the efficacy of GLP ‐1 receptor agonists: A systematic review and meta‐analysis of cardiovascular and renal outcome trials
di: Hasan Fareed Siddiqui, et al.
Pubblicazione: (2025)

Effects of GLP ‐1 receptor agonists on incidence and outcomes of ischemic stroke and myocardial infarction: A systematic review and meta‐analysis
di: Nawal Alammari, et al.
Pubblicazione: (2025)

Glucagon‐like peptide 1 ( GLP ‐1) receptor agonists' use during pregnancy: Safety data from regulatory clinical trials
di: Claire H. Parker, et al.
Pubblicazione: (2025)

Phase I study of the oral GLP ‐1 receptor agonist DA ‐ 302168S : Safety, pharmacokinetics, and pharmacodynamics in healthy and overweight/obese adults
di: Liang Zheng, et al.
Pubblicazione: (2025)

Association of GLP1 ‐receptor agonist use with liver disease progression, major cardiovascular events, and mortality in people with hepatic steatosis and diabetes
di: Suleiman Al Ashi, et al.
Pubblicazione: (2025)

The effect of GLP ‐1 receptor agonists on circulating inflammatory markers in type 2 diabetes patients: A systematic review and meta‐analysis
di: Yifan Ren, et al.
Pubblicazione: (2025)

The importance of treatment sequencing with SGLT2 inhibitors and GLP ‐1 receptor agonists combination for kidney function preservation in type 2 diabetes
di: Mario Luca Morieri, et al.
Pubblicazione: (2026)

No causal link between the supply of GLP ‐1 receptor agonists and antidepressants: Real‐world evidence from the Australian Pharmaceutical Benefits Scheme
di: Osvaldo P. Almeida, et al.
Pubblicazione: (2025)

Efficacy and safety of GLP ‐1 receptor agonists and SGLT2 inhibitors as adjuncts to insulin in type 1 diabetes: Systematic review and meta‐analysis
di: Sama M. Abdel‐Rahman, et al.
Pubblicazione: (2026)

Potential role of glucagon like peptide (GLP)‐1 receptor agonist to reduce risk of colorectal cancer?
di: Iskandar Idris
Pubblicazione: (2024)

Effectiveness of add‐on therapy with SGLT2 inhibitors or GLP ‐1 receptor agonists in adults with type 1 diabetes: A prospective DPV registry study
di: Christina Baechle, et al.
Pubblicazione: (2024)

One‐year usage patterns of SGLT ‐2 inhibitors and GLP ‐1 receptor agonists in individuals with type 2 diabetes in a real‐world population
di: Louise A. Donnelly, et al.
Pubblicazione: (2025)

Short‐term outcomes of switching from GLP ‐1 receptor agonists to tirzepatide in type 2 diabetes: A retrospective, observational study in clinical practice
di: Mari Matsushiro, et al.
Pubblicazione: (2025)

Effects of GLP ‐1 receptor agonists on cognitive function in patients with type 2 diabetes: A systematic review and meta‐analysis based on randomized controlled trials
di: Suxin Wan, et al.
Pubblicazione: (2025)

Risk of depression with GLP ‐1 receptor agonists use in overweight or obese adults with type 2 diabetes: A new‐user, active‐comparator cohort study
di: Yu Chang, et al.
Pubblicazione: (2025)

Binding kinetics, bias, receptor internalization and effects on insulin secretion in vitro and in vivo of a novel GLP ‐ 1R / GIPR dual agonist, HISHS ‐2001
di: Yusman Manchanda, et al.
Pubblicazione: (2025)

Efficacy of GLP ‐1 receptor agonists in patients with obesity and heart failure with preserved ejection fraction: A systematic review and meta‐analysis of randomised controlled trials
di: Armando Talavera, et al.
Pubblicazione: (2025)

Safety, pharmacokinetics and pharmacodynamics of multiple‐dose noiiglutide ( SHR20004 ), a novel GLP ‐1 receptor agonist, in Chinese obese subjects without diabetes mellitus
di: Yang Zou, et al.
Pubblicazione: (2024)

Prevalence of SGLT2 inhibitor and GLP1 receptor agonist prescriptions in type 2 diabetes patients with and without chronic kidney disease: Analysis of an Australian primary care dataset
di: Hannah Wallace, et al.
Pubblicazione: (2025)

Glucagon‐like peptide‐1 receptor agonists and mental health: A meta‐analysis of randomized controlled trials
di: Giovanni Antonio Silverii, et al.
Pubblicazione: (2024)

The safety, tolerability, pharmacokinetics and pharmacodynamics of an optimized dual GLP ‐1/ GIP receptor agonist ( BGM0504 ) in healthy volunteers: A dose‐escalation Phase I study
di: Yuxin Fan, et al.
Pubblicazione: (2025)

iGlarLixi : A titrateable fixed‐ratio combination of basal insulin + GLP‐1 receptor agonist—An effective type 2 diabetes treatment option in China
di: Miao Yu
Pubblicazione: (2025)

The role of incretin receptor agonists in the treatment of obesity
di: Thomas Forst, et al.
Pubblicazione: (2024)

A long‐acting glucose‐dependent insulinotropic polypeptide receptor agonist improves the gastrointestinal tolerability of glucagon‐like peptide‐1 receptor agonist therapy
di: Filip K. Knop, et al.
Pubblicazione: (2024)

GLP ‐1 receptor agonist therapy for relapsed diabetes following 6q24‐related transient neonatal diabetes due to paternal uniparental disomy: A case report
di: Francesco Giangreco, et al.
Pubblicazione: (2025)

Anti‐diabetic effects of GLP ‐1 receptor agonists on obese and overweight patients across diabetes status, administration routes, treatment duration and baseline characteristics: A systematic review
di: Hon Jen Wong, et al.
Pubblicazione: (2024)

Real‐world persistence and dose titration of GLP ‐1 receptor agonists in type 2 diabetes: A UK population‐based cohort study by obesity and cardiovascular disease status
di: Franziska S. Ulrich, et al.
Pubblicazione: (2026)

Subgroup analysis by sex and baseline BMI in people with a BMI ≥27 kg/m 2 in the phase 2 trial of survodutide, a glucagon/ GLP ‐1 receptor dual agonist
di: Carel W. le Roux, et al.
Pubblicazione: (2025)